Diligence memo · auto-generated · as of July 2, 2026
Adaptive Phage Therapeutics, Inc.
Adaptive Phage Therapeutics, Inc. looks fair against its niche peers and is at-risk on financing cadence.
Businessfiled
Adaptive Phage Therapeutics, Inc. operates in Pharmaceuticals, based in GAITHERSBURG.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Adaptive Phage Therapeutics, Inc. has raised $49M in disclosed capital across 6 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $23M on 2021-05-07.
Most recent recorded round closed around 2023-05-25.
Valuation (modeled)modeled
Provath models Adaptive Phage Therapeutics, Inc. at approximately $130M (range $25M–$287M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.00× the median modeled value of Series B Pharmaceuticals companies in 2022–2024 (51 peers) — value vs value, same stage and era. Within the normal band (100% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 11 months.
Last raise 3.1 yr ago; this sector typically re-raises about every 13 months.
Past due for a raise versus sector cadence — watch for distress or a bridge.
The last round was 1.9× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 81% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 60% of those peers.
Closest niche peers: MedAvail Holdings, Inc., Revalesio Corp, Kinaset Therapeutics, Inc., Venatorx Pharmaceuticals, Inc., Cxl Ophthalmics, Inc..
Peoplefiled
17 named people on file across officers, directors and signatories.
Risks & flagsmixed
Overdue for a raise versus sector norm — distress or bridge risk.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.